Skip to main content

Advertisement

Fig. 2 | Journal of Translational Medicine

Fig. 2

From: Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer

Fig. 2

HGF/MET pathway expression and activation in recurrent/metastatic HNSCC. a Representative pictures showing a range of EGFR, MET, p-MET, and HGF expression levels observed by IHC in human HNSCC. b MET identification in FFPE tissue samples by SISH. Left panel detail of a MET-amplified case (clusters of black dots are seen in the nuclei of tumoral cells, representing several copies of the MET locus; as opposed to just two red dots per cell, corresponding to the centromeric region on chromosome 7). Right panel non-amplified sample. c Protein expression levels and gene amplification in the complete series. Case numbers are ordered from test (#1–33) to controls (#34–57), and a dashed line has been drawn in between the two groups. The color intensity of the boxes is indicative of abundance level in each column, either protein level by IHC (EGRF, MET, p-MET, HGF) or gene amplification level by SISH (MET gene). Expression levels are indicated in a color gradient, from white (minimum) to red (maximum), with missing data in gray

Back to article page